Dexmedetomidine Attenuates LPS-Induced Monocyte-Endothelial Adherence via Inhibiting Cx43/PKC-α/NOX2/ROS Signaling Pathway in Monocytes

Figure 2

Dexmedetomidine attenuates U937-HUVEC adhesion and inhibits VAL-4 and LFA-1 expressions in U937 monocytes via downregulating the NOX2/ROS signaling pathway. (a) Effects of dexmedetomidine on the level of ROS in U937 monocytes (, vs. control; ^# vs. the LPS group; ^& vs. the 0.1 nM dexmedetomidine group). (b) Effects of dexmedetomidine on NOX2 expression in U937 monocytes (, vs. control; ^# vs. the LPS group). (c) Effects of NAC and GSK2795039 on the level of ROS in U937 monocytes (, vs. control; ^# vs. the LPS group). (d) Effects of GSK2795039 on NOX2 expression in U937 monocytes (, vs. control; ^# vs. the LPS group). (e) Effects of NAC and GSK2795039 on VLA-4 and LFA-1 expressions in U937 monocytes (, vs. control; ^# vs. the LPS group). (f) Effects of NAC and GSK2795039 on VLA-4 and LFA-1 expressions in U937 monocytes (, vs. control; ^# vs. the LPS group) and effects of NAC and GSK2795039 on U937-HUVEC adhesion (, vs. control; ^# vs. the LPS group).

(a)

(b)

(c)

(d)

(e)

(f)